Table 1.
Aetiology of hypopituitarism, additional hormone replacement, prevalence of diabetes mellitus in statin group (SG) and nonstatin group (NSG) and duration of statin use in SG
| Aetiology | SG (%) | NSG (%) |
|---|---|---|
| Pituitary adenoma | 66·6 | 72·1 |
| Craniopharyngioma | 6·4 | 6·6 |
| Other pituitary/hypopituitary tumours | 5·1 | 1·6 |
| Cranial tumours | 3·0 | 0 |
| Extracranial malignancy | 0·6 | 0 |
| Other causes acquired GHD | 13·6 | 18·0 |
| Idiopathic GHD | 4·7 | 1·6 |
| Hormone replacement | ||
| TSH | 70·8 | 68·8 |
| ACTH | 67·2 | 63·9 |
| LH/FSH | 78·3 | 78·7 |
| ADH | 23·4 | 16·4 |
| Diabetes mellitus | 4·4 | 18·0* |
| Duration of statin therapy before entry into KIMS† | 2·6 ± 2·7 SD | |
†
Only patients who were treated with statins for at least 1 year before entry into KIMS were included.
*
P < 0·0001. GHD, growth hormone deficiency.